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Abstract: Nanoscale secondary ion mass spectrometry (NanoSIMS) combined with transmission
electron microscopy (TEM) can be a powerful approach to visualize the exact distribution of
drugs at the sub-cellular level. In this work, we exploit this approach to identify the distribution
and localisation of the organometallic ruthenium(II)-arene drug Ru(η6-C6H5Me)(pta)Cl2, termed
RAPTA-T, in MDA-MB-231 and MCF-7 human breast cancer cells. These cell lines have been chosen
because the former cell lines are highly invasive and resistant to most chemotherapeutic agents and
the latter ones are very sensitive to hormonal-based therapies. In the MDA-MB-231 cells, RAPTA-T
was found to predominantly localise on the cell membrane and to a lesser extent in the nucleolus.
These findings are consistent with the previously reported anti-metastatic properties of RAPTA-T
and the observation that once internalized RAPTA-T is associated with chromatin. RAPTA-T shows
a lack of membrane accumulation on the non-invasive MCF-7 cells, which correlates well with its
selective anti-metastatic properties on invasive cell lines.
Keywords: breast cancer; invasion; metastasis; ruthenium
1. Introduction
Platinum-based drugs are widely used in the clinic [1,2]. However, in recent years, an increasing
number of ruthenium complexes, with profoundly different properties compared with the currently
used platinum drugs, e.g., higher cancer cell selectivity leading to reduced side-effects in vivo [3],
have been (pre-)clinically evaluated [4–7]. All these drugs possess the classical coordination
complexes structure, but there is now considerable interest in the anticancer properties of
organometallic complexes, i.e., those containing direct metal-to-carbon bonds [8,9]. Of these
organometallic compounds, the ruthenium(II)-arene drugs (Scheme 1), Ru(η6-arene)(pta)Cl2 where pta
= 1,3,5-triaza-7-phosphaadamantane, termed RAPTA compounds, are the most advanced in pre-clinical
studies, and many derivatives have been prepared and tested [10]. Specifically, Ru(η6-C6H5Me)(pta)Cl2
(RAPTA-T) possesses anti-metastatic properties in an in vitro model mimicking the detachment,
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invasion, migration, and re-attachment steps of metastasis formation [11]. This effect is much more
evident on the invasive MDA-MB-231 breast cancer cells than on non-invasive MCF-7 breast cancer
cells [11]. The in vitro studies were validated in an in vivo syngeneic, spontaneously metastasizing
mammary carcinoma murine model, which showed RAPTA-T treatment to be effective, resulting in a
reduction of lung metastasis formation of these tumours [12].
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as much data as possible on the behaviour of RAPTA-T in cells as a function of cellular characteristics 
and of their response to treatment. 
An approach that produces visual distribution maps of metal-based drugs in cells, nanoscale 
secondary ion mass spectrometry (NanoSIMS) [15] is attracting increasing attention [16] and has been 
used to image RAPTA-T in cisplatin-resistant human ovarian cancer (A2780CR) cells [17]. 
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receptors, and are therefore sensitive to hormonal-based therapies [19]. 
2. Results 
Secondary ion maps of 13C12C−/12C2−, 
14N12C−/12C2−, 
15N12C−/14N12C−, 31P−/12C2−, 
34S−/12C2−, and 
102Ru−/12C2−, as well as transmission electron microscopy (TEM) images of MDA-MB-231 cells treated 
with 15N/13C-labelled RAPTA-T (500 μM, 24 h), are shown in Figure 1. As observed previously in 
A2780CR cells treated with 15N+13C-labelled RAPTA-T [17], 13C enrichment was not observed in 
RAPTA-T treated MDA-MB-231 and MCF-7 cells indicating that the sample preparation dilutes the 
13C-isotopic enrichment from the 13C-enriched toluene ligand to below the detection limit [20]. In the 
MDA-MB-231 cells, all Ru hotspots found were co-enriched with 15N (Figure 1, green boxes), 
suggesting that the phosphine (PTA) ligand remains coordinated to the Ru centre. However, there 
were several 15N-enriched hotspots that did exhibit Ru enrichment, most likely due to detachment of 
PTA from Ru. 
RAPTA-T was found to accumulate in the nucleolus of MDA-MB-231 cells (Figure 1). This 
observation is consistent with other studies in which RAPTA-T has been shown to interact with the 
histone proteins that package and order DNA into nucleosomes [21]. Accumulation of RAPTA-T was 
also observed on the cell membrane of MDA-MB-231 cells where it could interact with extracellular 
cell adhesion proteins implicated in its anti-metastatic activity [11]. Overlaying the 102Ru− and 12C15N− 
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RAPTA-T is not the only compound of this family that has the capacity to reduce metastasis
formation in experimental models [12]. However, RAPTA-T has other favourable physico-chemical and
biological characteristics, i.e., particularly good water solubility and an intrinsic cancer cell selectivity
demonstrated by a cytotoxicity difference between tumorigenic (74 µM) and non-tumorigenic
(>1000 µM) cells [12], making it suitable for pharmacological development. Nevertheless,
the development of RAPTA-T is also dependent on knowledge about its biological and pharmacological
mode of action. Although RAPTA-T was not derived from a targeted approach, but essentially from the
upgrading of clinically used platinum drugs [13], its mode of action is profoundly different, binding
preferentially to proteins rather than DNA [14]. It is therefore necessary to acquire as much data as
possible on the behaviour of RAPTA-T in cells as a function of cellular characteristics and of their
response to treatment.
An approach that produces visual distribution maps of metal-based drugs in cells, nanoscale
secondary ion mass spectrometry (NanoSIMS) [15] is attracting increasing attention [16] and has
been used to image RAPTA-T in cisplatin-resistant human ovarian cancer (A2780CR) cells [17].
Consequently, the aim of the present study is to determine the distribution of RAPTA-T in MDA-MB-231
and MCF-7 cells and to probe whether any difference in distribution exists between these cells
possessing different metastatic phenotypes. Both MCF-7 and MDA-MB-231 are breast cancer
adenocarcinomas isolated from pleural effusions [18]. MDA-MB-231 are a triple-negative cell
line lacking oestrogen and progesterone receptors in which the human epidermal growth factor
receptor 2 (HER2/Neu) is not amplified, making it resistant to most chemotherapeutic agents. These
characteristics differ to MCF-7 cells, which are positive for both oestrogen and progesterone receptors,
and are therefore sensitive to hormonal-based therapies [19].
2. Results
Secondary ion maps of 13C12C−/12C2−, 14N12C−/12C2−, 15N12C−/14N12C−, 31P−/12C2−,
34S−/ 2−, and 102Ru−/12C2−, as well as transmission electron microscopy (TEM) images of
MDA-MB-231 cells treated with 15N/13C-labelled RAPTA-T (500 µM, 24 h), are shown in Figure 1.
As observed previously in A2780CR cells treated with 15N+13C-labelled RAPTA-T [17], 13C enrichment
was not observed in RAPTA-T treated MDA-MB-231 and MCF-7 cells indicating that the sample
preparation dilutes the 13C-isotopic enrichment from the 13C-enriched toluene ligand to below the
detection limit [20]. In the MDA-MB-231 cells, all Ru hotspots found were co-enriched with 15N
(Figure 1, green boxes), suggesting that the phosphine (PTA) ligand remains coordinated to the Ru
centre. However, there were several 15N-enriched hotspots that did exhibit Ru enrichment, most likely
due to detachment of PTA from Ru.
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In MCF-7 cells, the accumulation profile of RAPTA-T is in part similar to that in MDA-MB-231 
cells, i.e., with accumulation in the nucleolus and a general co-accumulation of the drug at sulphur-
rich hotspots (Figure 2). However, in contrast to MDA-MB-231 cells, accumulation of RAPTA-T was 
not observed in the nucleus or on the cell membrane of MCF-7 cells. From the overlaid TEM images, 
RAPTA-T was also found to accumulate partially in mitochondria and cytoplasmic vacuoles. The 
lack of distribution in the nucleus and membrane of MCF-7 cells could partially explain the weaker 
activity of RAPTA-T in preventing migration, detachment, and reattachment of these cells compared 
to MDA-MB-231 cells. 
Figure 1. NanoSIMS secondary ion maps of 31P /12C2−, 34S−/12C2−, 14 12 /12C2 ,
15N12C−/14N12C−, 102Ru−/12C2−, and 13C12C−/12C2− and TEM images of MDA-MB-231 c lls
treated with 15N/13C-labelled RAPTA-T (500 µM, 24 h). Blue boxes indicate Ru-enriched hotspots,
yellow boxes indic te 15N-enriched hotspots, and green boxes indicate hotspots co-enriched with 15N
and Ru. Cellular organelles are labeled in the TEM image.
RAPTA-T was found to accumulate in the nucleolus of MDA-MB-231 cells (Figure 1).
This observation is consistent with other studies in which RAPTA-T has been shown to interact
with the histone proteins that package and order DNA into nucleosomes [21]. Accumulation of
RAPTA-T was also observed on the cell membrane of MDA-MB-231 cells where it could interact with
extracellular cell adhesion proteins implicated in its anti-metastatic activity [11]. Overlaying the 102Ru−
and 12C15N− maps with TEM images reveals that RAPTA-T also accumulate partially in cytoplasmic
vacuoles, which are potential drug targets [22,23], and in mitochondria. The distribution and action
of RAPTA-T in mitochondria has been reported previously, where treatment with the drug resulted
in an appreciable accumulation in mitochondrial fractions from A2780CR cells [24] and results in
perturbation of the expression of several mitochondrial proteins [25]. RAPTA-T accumulation tends to
correlate with the sulphur-rich regions of the MDA-MB-231 cells, which is not surprising considering
that most organelles in which RAPTA-T is distributed contain sulphur-rich biomolecules.
In MCF-7 cells, the accumulation profile of RAPTA-T is in part similar to that in MDA-MB-231
cells, i.e., with accumulation in the nucleolus and a general co-accumulation of the drug at sulphur-rich
hotspots (Figure 2). However, in contrast to MDA-MB-231 cells, accumulation of RAPTA-T was not
observed in the nucleus or on the cell membrane of MCF-7 cells. From the overlaid TEM images,
RAPTA-T was also found to accumulate partially in mitochondria and cytoplasmic vacuoles. The lack
of distribution in the nucleus and membrane of MCF-7 cells could partially explain the weaker
activity of RAPTA-T in preventing migration, detachment, and reattachment of these cells compared
to MDA-MB-231 cells.
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previously that A2780CR cells, unlike their cisplatin-sensitive (A2780) counterparts, undergo 
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3. Discussion
Accumulation of RAPTA-T in the membrane of human breast cancer cell lines is significantly
higher in the invasive MDA-MB-231 cell line compared to MCF-7 cells. Such differences in RAPTA-T
accumulation must be due to differences in the cell type and phenotype. It has been shown
previously that A2780CR cells, unlike their cisplatin-sensitive (A2780) counterparts, undergo metastasis
and shorten survival rates of mice xenografted with these cells [26]. Hence, both A2780CR and
MDA-MB-231 cells are highly invasive, and the selective membrane association of RAPTA-T with these
cell lines might be correlated with the anti-metastatic properties of the compound. This selectivity
is exemplified by the lack of membrane accumulation of RAPTA-T on the less invasive MCF-7 cells.
Notably, in the A2780CR and MDA-MB-231 cell lines, the amount of RAPTA-T associated with the
membrane exceeds that inside the cells.
The distribution of RAPTA-T inside both cell lines is largely associated with accumulation in the
nucleolus. Interestingly, RAPTA-C, a closely related compound to RAPTA-T, has been shown to reduce
proliferation, migration, and tube formation in endothelial cells and also stimulate apoptosis [27].
These effects may be attributed to interactions of RAPTA-C with the endothelial cell membrane and to
epigenetic factors.
Overall, the differences observed in the NanoSI S studies provide new insights into how
RAPTA-T distribution correlates with the phenotypic changes induced by its activity on cancer cells.
These data emphasise the role of targeting molecules to the cell membrane for the control of metastasis
of solid tumours. This aspect has already been stressed for the ruthenium(III) drug, NAMI-A, another
potent anti-metastatic drug, which has been shown to bind to integrins [28]. If it is found that RAPTA-T
is also able to target integrins, integrin modulation could become a highly attractive approach for
tumour control with metal-based drugs. Such a mechanism, which is profoundly different to the
development of DNA-damaging metal-based drugs [29], would stimulate the search for novel, selective
drugs to control tumour malignancy.
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4. Materials and Methods
4.1. Synthesis and Characterisation of 13C/15N Labelled RAPTA-T
15N enriched 1,3,5,7-tetraazatricyclo[3.3.1.1 (3,7)]decane (PTA) was synthesized according to a
literature method [30], with minor modifications consisting in the replacement of 14NH4OH with
15NH4OH in the described procedure [31]. 13C labelled metyl-cyclohexadiene was prepared from
a birch reduction of toluene-(phenyl-13C6) and used to prepare 15N/13C-RAPTA-T (Scheme 2) as
described previously [17].
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Scheme 2. Structure of 15N/13C labelled RAPTA-T. Characterisation: 1H NMR (400 MHz, Methanol-d4) 
= δ 5.95–5.22 (m, 5H), 4.60 (s, 6H), 4.35 (s, 6H), 2.17 (s, 3H). 13C NMR (101 MHz, Methanol-d4) only 
enriched 13C = δ 108.33, 88.64–85.31 (m), 77.87–75.73 (m). 31P NMR (162 MHz, Methanol-d4) = δ 33.43. 
HRMS (ESI+) m/z calculated for C713C6H20Cl15N3PRu [M-Cl+H]+: 395.0239; found: 395.0242. 
4.2. Cell Culture 
MDA-MB-231 and MCF-7 (human breast adenocarcinoma) cells were cultured in DMEM 
medium supplemented with 10% foetal calf serum, penicillin 100 units/mL, and streptomycin 100 
μg/mL (Invitrogen, Carlsbad, CA, USA). Cells were incubated at 37 °C in a humid environment 
containing 5% CO2. 
4.3. Cell Preparation 
Cells were seeded 50,000 cells/well in 24-well or 500,000 cells/well in 6-well clear bottom plates 
fitted with sapphire disks. After 24 h, cell media was aspirated and fresh media containing 15N and 
13C-RAPTA-T (500 μM) was added (a high concentration of compound was used due to the reduced 
incubation time). Upon incubation, the sapphire disks were removed from the media and then high 
pressure frozen (Leica HPM100, Leica Microsystems, Wetzlar, Germany) with excess 20% BSA 
solution in 0.01 M PBS (phosphate buffer solution) to avoid any air bubbles becoming trapped and 
the formation of ice crystals. The frozen cells were then embedded in resin at low temperature [32]. 
The sapphire discs were placed on a frozen solution of 1% osmium, 0.5% uranyl acetate, 5% water in 
acetone. The samples where then warmed to room temperature in an ice bucket containing solid 
carbon dioxide blocks that were allowed to sublime over a period of 2 h until they reached room 
temperature. At this point the solution was removed and replaced with dry acetone. After washing 
twice with acetone, the samples were embedded in increasing concentrations of epon resin in acetone. 
At 100% concentration of resin, the samples were then left overnight to fully infiltrate and then 
polymerised in a 60 °C oven for at least 12 h. Samples where then glued to empty resin blocks, 
trimmed, and sections of alternating thickness of 500 nm and 50 nm cut sequentially from the face. 
The thicker sections were collected onto a glass coverslip stained with 1% touldine blue and imaged 
with light microscopy and NanoSIMS. The 50 nm thick sections were collected on to an electron 
microscopy slot grid ready for imaging with transmission electron microscopy at a final 
magnification of around 1400 times (Tecnai Spirit, FEI Company, Eindhoven, The Netherlands). 
4.4. NanoSIMS Analysis 
NanoSIMS measurements were performed at the Laboratory of Biological Geochemistry, EPFL 
and the University of Lausanne. Prior to NanoSIMS imaging the samples were gold-coated in order 
to avoid charging effects. Before acquiring an image, Cs+ ions were implanted into the surface of the 
Scheme 2. Structure of 15N/13C labelled RAPTA-T. Characterisation: 1H NMR (400 MHz, Methanol-d4)
= δ 5.95–5.22 (m, 5H), 4.60 (s, 6H), 4.35 (s, 6H), 2.17 (s, 3H). 13C NMR (101 MHz, Methanol-d4) only
enriched 13C = δ 108.33, 88.64–85.31 (m), 77.87–75.73 (m). 31P NMR (162 MHz, Methanol-d4) = δ 33.43.
HRMS (ESI+) m/z calculated for C713C6H20Cl15N3PRu [M-Cl+H]+: 395.0239; found: 395.0242.
4.2. Cell Culture
MDA-MB-231 and MCF-7 (human breast adenocarcinoma) cells were cultured in DMEM medium
supplemented with 10% foetal calf serum, penicillin 100 units/mL, and streptomycin 100 µg/mL
(Invitrogen, Carlsbad, CA, USA). Cells were incubated at 37 ◦C in a humid environment containing
5% CO2.
4.3. Cell Preparation
Cells ere seeded 50,000 cells/ ell in 24- ell or 500,000 cells/ ell in 6- ell clear botto plates
fitted ith sapphire disks. After 24 h, cell media was aspirated and fresh media containing 15N
and 13C-RAPTA-T (500 µM) was added (a high concentration of compound was used due to the
reduced incubation time). Upon incubation, the sapphire disks were re oved from the media and
then high pressure frozen (Leica HPM100, Leica Microsystems, Wetzlar, Germany) with excess 20%
BSA solution in 0.01 M PBS (phosphate buffer solution) to avoid any air bubbles becoming trapped
and the formation of ice crystals. The frozen cells were then embedded in resin at low temperature [32].
The sapphire discs ere placed on a frozen solution of 1 os iu , 0.5 uranyl acetate, 5 ater in
acetone. The samples where then warmed to room temperature in an ice bucket containing solid carbon
dioxide blocks that were allo ed to sublime over a period of 2 h until they reached room temperature.
At this point the solution was removed and replaced with dry acetone. After washing twice with
acetone, the samples were embedded in increasing concentrations of epon resin in acetone. At 100%
concentration of resin, the samples were then left overnight to fully infiltrate and then polymerised in
a 60 ◦C oven for at least 12 h. Samples where then glued to empty resin blocks, trimmed, and sections
of alternating thickness of 500 nm and 50 nm cut sequentially fro the face. The thicker sections
were collected onto a glass coverslip stained with 1% touldine blue and imaged with light microscopy
and NanoSIMS. The 50 nm thick sections were collected on to an electron microscopy slot grid ready
for imaging with transmission electron microscopy at a final magnification of around 1400 times
(Tecnai Spirit, FEI Company, Eindhoven, The Netherlands).
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4.4. NanoSIMS Analysis
NanoSIMS measurements were performed at the Laboratory of Biological Geochemistry, EPFL
and the University of Lausanne. Prior to NanoSIMS imaging the samples were gold-coated in order
to avoid charging effects. Before acquiring an image, Cs+ ions were implanted into the surface of the
sample in order to enhance the ionization of the element of interest. The electron multiplier detectors
were set up to measure 12C2−, 13C12C−, 12C14N−, 12C15N−, 31P−, 34S−, and 102Ru− secondary ions,
generated by bombarding the sample with a ~4 pA Cs+ primary beam focused to a spot size of
approximately 160 nm. In order to resolve possible isobaric interferences, the instrument was operated
at a mass-resolving power (MRP) of about 10,000. Due to the low signal of 102Ru− obtained from
cells, peak-shape and mass resolving power was checked using a Ru standard. Data acquisition was
performed by scanning the Cs+ primary beam over areas of 34 × 34 µm with a 256 × 256 pixel image
resolution. The per pixel dwell time of the primary ion beam was 10 ms. The final images are the
accumulation of 120 layers obtained by sequential scanning and correspond to a cumulated acquisition
time per pixel of 1.2 s. Between every layer, the transmission of the secondary ion beam was optimized
and automatic peak centring was performed for 12C2−, 13C12C−, 12C14N−, 12C15N−. The Ru peak
could not be centred due to the low count rates. However, post-analysis checks revealed that there was
no significant change in the peaks position during the entire acquisition time. The total acquisition
time including the centring procedure was 22 h per image.
4.5. Data Extraction and Image Processing
NanoSIMS image processing was performed with L’image (L. Nittler, Carnegie Institution of
Washington, Washington, DC, USA). Over the ~20 h of image acquisition, the image drift of a
34 × 34 µm image was less than 7 pixels (i.e., less than 1 µm). The data reduction software can
easily correct for such a drift by aligning the positions of identified structures. Regions of interest (ROI)
were defined manually based on identifiable cell features on the 31P− elemental map. Images were
accumulated from planes where accumulated counts per ROI were stable with 12C14N− used as the
alignment mass. All other elements were normalized against 12C2, the images of which are essentially
flat, to normalize out small ionization variations across the sample surface.
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